TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02243605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00998608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: risperidone 4mg/d
Study: NCT03328299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: 20 ml of 0.5 % bupivacaine
Study: NCT02676375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Bupropion + NRTs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Bupropion + NRTs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Visits & Calls

Intervention type: DRUG
Group type: OTHER
Intervention: Monotherapy
Study: NCT00508430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral
Study: NCT00267969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
Study: NCT00508430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03842995

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Genetic Counselor
Description: Standard of Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trained Healthcare Provider
Description: Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
Study: NCT05261152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
Description: Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug product: capsules are containing S. boulardii, administered twice daily (250 mg)
Description: Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
Study: NCT00907829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: comparison of the effect of the drug to help improve finger function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle stimulator
Description: comparison of the effect of stimulated muscle(s) on finger function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle stimulator
Description: comparison of the effect of stimulated muscle(s) on finger function
Study: NCT03548740

Intervention type: BIOLOGICAL
Intervention: Human Papillomavirus
Description: women with high-risk Human Papillomavirus or not
Study: NCT03091374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin (Human)
Study: NCT04421781

Intervention type: OTHER
Intervention: Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT
Description: Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
Study: NCT01309633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Sunitinib alternating with Cisplatin and Gemcitabine
Description: Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
Description: Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
Study: NCT01716429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Vegan dietary approaches for weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Reduced calorie diet for weight loss
Study: NCT01437748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: Dry powder, 300 mcg, only one inhalation with 24 hours duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide
Description: Dry powder, 18 mcg, only one inhalation with 24 hours duration
Study: NCT00413387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate plus formoterol fumarate combination
Description: 100mcg beclomethasone diproprionate plus 6 mcg formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide plus formoterol combination
Description: 200mcg budesonide plus 6 mcg formoterol
Study: NCT02316795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goggle-based device with light-emitting diodes (LED)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocynanine Green
Description: This is a infrared fluorescence imaging contrast agent
Study: NCT03998787

Intervention type: OTHER
Intervention: Neurophysiological assessment
Description: Kinematic analysis of movement and transcranial magnetic stimulation

Intervention type: OTHER
Intervention: Neurophysiological assessment
Description: Kinematic analysis of movement and transcranial magnetic stimulation
Study: NCT02846623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT00267969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
Study: NCT02846623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03583554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 4 placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 4 placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 4 placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101 720 mg
Description: Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101 720 mg
Description: Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AV-101 720 mg
Description: Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101 1440 mg
Description: Single dose of 4 360 mg AV-101 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101 1440 mg
Description: Single dose of 4 360 mg AV-101 oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AV-101 1440 mg
Description: Single dose of 4 360 mg AV-101 oral capsules
Study: NCT03934398

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Assessments
Description: Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessments
Description: Participants will provide blood and urine samples for laboratory assessments.

Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional/Behavioral Assessments
Description: Participants and parents will fill out questionnaires for emotional/behavioral assessments
Study: NCT00226239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV over 1 hour, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies\>6 MV may be utilized when appropriate to boost target localized centrally.
Study: NCT02808624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-CARNOSINE
Description: L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
Study: NCT06535048

Intervention type: DRUG
Intervention: Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
Description: Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks.

Intervention type: DRUG
Intervention: Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
Description: Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks.
Study: NCT01800968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01725828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using the Ultrasound to determine the location of the CTM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Palpation
Description: Using External Palpation to identify cricothyoid membrane
Study: NCT00054431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02937168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab will be administered as per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18 (FDG)
Description: FDG will be administered by IV infusion prior to each PET/CT scan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludeoxyglucose F 18 (FDG)
Description: FDG will be administered by IV infusion prior to each PET/CT scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18 (FDG)
Description: FDG will be administered by IV infusion prior to each PET/CT scan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
Study: NCT02543034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Betafoam Wound Dressing
Description: Foam dressing including Betadine iodine
Study: NCT04283149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVO/EVO+ Visian ICL
Description: The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
Study: NCT02543034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum Gauze
Description: Gauze dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allevyn Wound Dressing
Description: Foam dressing
Study: NCT04217681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Description: It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music/self-care
Description: It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care motivation
Description: It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care malignant pain
Description: It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
Study: NCT01506193

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTetra™
Description: One dose administered subcutaneously
Study: NCT03080064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach Intervention
Description: Please see arm description.
Study: NCT03191461

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine stress test MRI
Description: Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine stress test MRI
Description: Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
Study: NCT00650013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl Tablets 5 mg
Description: 5mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAmatine® Tablets 5 mg
Description: 5mg, single dose fed
Study: NCT01167933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Study: NCT01209949

Intervention type: DRUG
Group type: OTHER
Intervention: Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
Description: Apply adapalene BPO gel once daily in the evening for 12 weeks
Study: NCT00461773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg po qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: bevacizumab 10 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: bevacizumab 10 mg/kg IV
Study: NCT02917291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAB117-HC
Description: (Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: (Ph 2) No treatment will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAB117-HC
Description: (Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
Study: NCT04478695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: Continuous intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 330
Description: Continuous intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.
Study: NCT05808426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonus Winner Mahjong
Description: Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
Study: NCT04283799

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A new human milk fortifier
Description: Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
Study: NCT03032042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole

Intervention type: DRUG
Group type: OTHER
Intervention: Delayed treatment
Description: Albendazole+Azithromycin
Study: NCT02277652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy
Study: NCT03697512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: capsules for oral intake in a dosage of 560 mg (four capsules) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.